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http://dx.doi.org/10.1016/j.stemcr.2016.08.003SUMMARYDown syndrome (DS) is the leading genetic cause of mental retardation and is caused by a third copy of human chromosome 21. The
different pathologies of DS involve many tissues with a distinct array of neural phenotypes. Here we characterize embryonic stem cell
lineswithDS (DS-ESCs), and focus on the neural aspects of the disease. Our results show that neural progenitor cells (NPCs) differentiated
fromfive independent DS-ESC lines display increased apoptosis and downregulation of forehead developmental genes. Analysis of differ-
entially expressed genes suggested RUNX1 as a key transcription regulator in DS-NPCs. Using genome editing we were able to disrupt all
three copies of RUNX1 in DS-ESCs, leading to downregulation of several RUNX1 target developmental genes accompanied by reduced
apoptosis and neuron migration. Our work sheds light on the role of RUNX1 and the importance of dosage balance in the development
of neural phenotypes in DS.INTRODUCTION
Down syndrome (DS) is the leading genetic cause ofmental
impairment (Pulsifer, 1996), resulting from an extra copy
of human chromosome 21. Individuals with DS display
various phenotypes that affect multiple tissues (Korenberg
et al., 1994), themost prevalent of which include cognitive
defects, premature Alzheimer’s disease, aging, and distinct
dysmorphic facial features (Briggs et al., 2013; Galdzicki
et al., 2001; Roizen and Patterson, 2003). It is thought
that the pathologies of DS result from dosage sensitivity
of several genes that play a role in the development of
different tissues, and from inter- and intra-chromosomal
regulatory interactions (Briggs et al., 2013).
Although chromosome 21 harbors about 350 genes, only
a minimal region of about 50 genes within the chromo-
some is responsible for most of the phenotypes associated
with DS. This region, which localizes to the long arm
of chromosome 21, is considered the ‘‘DS-critical region’’,
and a third copy of this region is sufficient to cause
most of the phenotypes of DS (Briggs et al., 2013; Delabar
et al., 1993; Dierssen, 2012; Korenberg et al., 1994;
McCormick et al., 1989; Me´garbane´ et al., 2009; Rahmani
et al., 1989). Genes within the DS-critical region also play
an important transcriptional regulatory role in different
developmental processes. Thus, the effect of the dosage
imbalance is not limited to genes on chromosome 21
alone, but also extends to target genes found on other
chromosomes.
Mouse models for DS have been the primary tool for
studying this disorder in past years. The most complex
mouse models developed to study DS are either mice con-Stem Cell Re
This is an open access article under the Ctaining a third copy of three chromosomal regions or-
thologous to human chromosome 21, or mice carrying
the complete human chromosome 21 as an extra copy
(O’Doherty et al., 2005; Yu et al., 2010). These and other
mousemodels have proved to be very useful in understand-
ing different aspects of the disorder. However, several DS
phenotypes are not recapitulated due to limitations of
genetic engineering or inter-species differences (Dierssen,
2012; Olson et al., 2004).
The use of embryonic stem cells (ESCs) for disease
modeling has enabled the study of numerous human disor-
ders that could not have been modeled in animals due to a
lack of relevant phenotypes, appearance of different phe-
notypes, or even embryonic lethality (Avior et al., 2016;
Halevy and Urbach, 2014). In contrast to induced pluripo-
tent stem cells (iPSCs), which are reprogrammed from adult
cells, ESC models for human disorders are derived from
early embryos that were found to carry a mutation or a
chromosomal aberration by preimplantation genetic diag-
nosis (PGD) or preimplantation genetic screening (PGS),
respectively. This difference is important in modeling syn-
dromes such as DS, as only a small fraction of trisomy-21
embryos survive to term (Morris et al., 1999; Spencer,
2001). By analyzing ESCs derived from early-stage em-
bryos, we can study the molecular pathways altered by
the presence of a third copy of chromosome 21more faith-
fully, as well as the ways in which this chromosomal aber-
ration may affect embryonic development.
We have previously isolated three PGS-derived ESC lines
with trisomy 21, and suggested that ESCs carrying a third
copy of chromosome 21 can be used as an in vitro model
forDS (Biancotti et al., 2010).Wehave furtherdemonstratedports j Vol. 7 j 777–786 j October 11, 2016 j ª 2016 The Author(s). 777
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Cellular Characterization of DS-ESCs
Karyotype analysis was performed on all five DS cell lines.
(A) Metaphases of the five cell lines CSES13, 20, 21, 32, and 44 show a third copy of chromosome 21 in all lines (47,XX,+21 or 47,XY,+21).
CSES32 and CSES44 cell lines were characterized for markers of pluripotent stem cells.
(B) CSES32 and CSES44 colonies stained positive for alkaline phosphatase.
(C) CSES32 and CSES44 colonies show positive staining for OCT4.
(D) All DS-ESC lines show expression of pluripotent genes such as NANOG, SOX2, and OCT4 similar to WT cells. The WT column represents the
average of three different WT cell lines, and the DS column represents the average expression level of five different DS cell lines. Error bars
represent SEM.
(E) CSES32 and CSES44 cell lines were differentiated in vivo by injecting them into immunodeficient mice to create teratomas. Teratoma
sectioning and staining with H&E show differentiation into the three germ layers: EC marks ectoderm, ME marks mesoderm, and EN marks
endoderm.by global gene-expression analysis that the third copy of
chromosome21 is actively transcribed inDS-ESCs (Biancotti
et al., 2010). In this study,weanalyzedneuraldifferentiation
of five individual DS-ESC lines to identify molecular and
cellular pathways involved in the development of this dis-
ease. Our data point to RUNX1, a gene that resides within
the DS-critical region, as a key transcriptional regulator in
DS neural progenitor cells (DS-NPCs). The contribution of
this gene to themolecular phenotype ofDSwas further vali-
dated by its disruption via gene editing.778 Stem Cell Reports j Vol. 7 j 777–786 j October 11, 2016RESULTS
To investigate the molecular and cellular phenotypes per-
turbed in DS, we compared DS and normal ESCs and their
neural derivatives. In the past, we have isolated three
DS-ESC lines, namely CSES13, CSES20, and CSES21, from
PGS-derived embryos with trisomy of chromosome 21 (Fig-
ure 1A) (Biancotti et al., 2010). To extend the number of
analyzed DS-ESC lines, we have established two additional
DS-ESC lines, CSES32 and CSES44, which also carry
trisomy 21 (Figure 1A). These DS-ESC lines were character-
ized in terms ofmorphology, alkaline phosphatase staining
(Figure 1B), and expression of OCT4 (Figure 1C). All five
DS-ESC lines showed expression of characteristic markers
of pluripotent stem cells with average expression levels
similar to those of wild-type (WT) cells (Figure 1D). Finally,
CSES32 and CSES44 DS-ESC lines were differentiated into
cells from the three embryonic germ layers upon induction
of teratomas in vivo, showing structures of endodermal,
mesodermal, and ectodermal tissues (Figure 1E).
To better understand the neural phenotype of DS cells
compared with normal cells, we differentiated all five DS-
ESC lines into NPCs. Gene-expression analysis shows that
in DS-ESCs, embryoid bodies (EBs), and NPCs, the relative
expression of genes on chromosome 21 is about 1.5-fold
higher than that of genes on chromosomes 20 or 22 (Fig-
ure 2A). These data suggest that in both undifferentiated
and differentiated DS cells, all three copies of chromosome
21 are actively transcribed. This upregulation, however, ac-
counts for only aminority of the differences observed in the
global gene-expression profile between normal and DS-
ESCs. Notably, the majority of the differentially expressed
genes between the two cell typeswere located onautosomal
chromosomes other than chromosome 21. Because DS
patients have a striking developmental phenotype related
to the CNS, we focused on the neural phenotype of DS-
NPCs. To study the neural phenotype, we compared data
of expression arrays of NPCs of three differentWTcell lines
with those of five different DS cell lines. The genes were
then sorted according to their expression levels, whereas
genes expressed more than 2-fold in DS-NPCs compared
with WT-NPCs were considered to be upregulated in DS,
while genes expressed less than 0.5-fold in DS-NPCs were
considered to be downregulated. Functional annotation
analysis of differentially expressed genes between DS- and
control NPCs using theDatabase for Annotation, Visualiza-
tion and Integrated Discovery (DAVID) (Huang et al.,
2009a, 2009b) showed downregulation of genes related to
forebrain development and upregulation of genes related
to apoptosis (Figure 2B). The forebrain developmental
genes downregulated in DS-NPCs include key neuronal
genes such as POU3F2 (also known as BRN2) and ASCL1
(Figure 2C). To verify the predicted changes in apoptosis,
weperformedflowcytometry analysis to quantify the levels
of programmed cell death in DS-NPCs derived from the five
DS cell lines and compared themwith controlNPCs derived
from three WT cell lines. The results showed an increase in
the tendency of DS-NPCs to activate apoptosis when
compared with control NPCs, assessed from the popula-
tions of both annexin V+/propidium iodide (PI) and an-
nexin V+/PI+ cells (Figure 2D).
We next analyzed whether the differential expression of
genes we observed in DS cells results, at least partly, froman extra copy of a transcription factor residing on chromo-
some21. For this purpose,weanalyzed all upregulated genes
with at least 2-fold change of expression in DS-NPCs, the
majority of which reside on the autosomes other than chro-
mosome 21 (Figure 3A), using the Promoter Integration in
Microarray Analysis (PRIMA) software that searches for
binding site enrichments on a given promoter set (Elkon
et al., 2003). The analysis found the binding site of the nu-
clear protein Runt-related transcription factor 1 (RUNX1)
to be significantly and highly enriched in the upregulated
genes (p < 0.05 with 3.5-fold enrichment) (Figure 3B).
RUNX1 is a transcription factor that localizes to the critical
region of chromosome 21 (Figure 3B). To better understand
the involvement of RUNX1 in the molecular pathology of
DS, we used the CRISPR/Cas9 gene-editing system and de-
signed a guide RNA to specifically target all isoforms of
RUNX1 in DS-ESCs and create DS-CRISPR-deleted RUNX1
(DSCR)ESCs toobserve themaximal effect ofRUNX1dosage
differences (Figure 3C). Among the various clones isolated,
we identified two clones, DSCR8 and DSCR75, with com-
plete ablationof theRUNX1proteinbywesternblot analysis
(Figure 3D), indicating disruption of all threeRUNX1 alleles.
Next, we differentiated the twoDSCR clones into NPCs and
performed global gene-expression analysis byDNAmicroar-
rays. We found that 162 genes were downregulated in our
DSCR-NPCs compared with their isogenic DS-NPCs. We
then analyzed these downregulated genes using the DAVID
software and the USCS transcription factor binding site
search.The analysis revealed thatnearly 70%of the downre-
gulated genes in the DSCR-NPCs (111 genes) were putative
targets of RUNX1 with a Benjamini-corrected p value of
0.026. Among the downregulated targets of RUNX1 are
several key developmental genes (Figure 4A), with some
genes such as IGFBP5, CCL2, LGR5, FBLN5, and TLR4
showing a RUNX1-dosage-dependent expression (Fig-
ure 4B). One of these genes, CCL2, showed amuch stronger
downregulation when analyzed by qRT-PCR (using the
primers listed in Table 1) compared with the expression
array data, probably due to a less stringent probe set in the
expression array. Functional annotation analysis revealed
that the downregulated genes in DSCR-NPCs were enriched
for neuron/cell migration and regulation of cell growth
(Figure 4C). Finally, we analyzed whether the ablation of
RUNX1 allowed the correction of the cellular phenotype
of apoptosis. Indeed, flow cytometry analysis demonstrated
that the DSCR clones had a reduced level of apoptosis when
compared with their parental DS lines (Figure 4D).DISCUSSION
Much of our knowledge onDS comes from the documenta-
tion of symptoms in patients and analysis of mouseStem Cell Reports j Vol. 7 j 777–786 j October 11, 2016 779
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models. Although the contribution of both sources has
been crucial in gaining a better understanding of the syn-
drome, the molecular pathways leading to the develop-
ment of DS are still largely unknown. The derivation of
ESCs with trisomy 21 enabled us to study the molecular
processes that underlie DS in human cells and address
questions that could not be addressed in other models. In
recent years several studies have used both ESCs and iPSCs
with trisomy 21 to study different aspects of DS such as he-
matopoiesis, heart development, and neural differentia-
tion (Bosman et al., 2015; Chang et al., 2015; Chou et al.,
2012; Maclean et al., 2012; Murray et al., 2015). Our
analysis of DS-NPCs showed aberrant expression of key
neuronal genes. In fact, two of the downregulated genes
in DS-NPCs, POU3F2 and ASCL1, have been used together
with MYT1L for direct conversion of fibroblasts into
functional neurons, thus highlighting the developmental
perturbation of DS cells (Vierbuchen et al., 2010). In recent
years, the role of RUNX1 in neural development has been
studied in different models. These studies suggested that
RUNX1plays an important role in the proliferation and dif-
ferentiation of NPCs, the control of neurite outgrowth, and
the impact on axonal pathfinding (Inoue et al., 2008; Ther-
iault et al., 2005; Yoshikawa et al., 2015, 2016). Moreover,
RUNX1 has been suggested to play a role in the peripheral
and CNS development, in defining different brain com-
partments and in consolidation of specific neuronal iden-
tity in the developing mouse nervous system (Levanon
et al., 2001; Simeone et al., 1995; Stifani et al., 2008; Zagami
and Stifani, 2010). However, the role of RUNX1 in human
neural development is still obscure. RUNX1 has been asso-
ciated with DS in terms of its contribution to the increased
risk of leukemia as seen in DS patients (De Vita et al., 2010).
However, the involvement of RUNX1 in the neural pheno-
type of the syndrome has not been fully addressed. Based
on our experimental data, we suggest that the extra
copy of RUNX1 in DS-NPCs may disrupt different molecu-
lar pathways during neural development. This in turn
could lead to perturbation in forebrain development andFigure 2. Molecular Characterization of DS-NPCs
All five DS cell lines were differentiated into EBs and NPCs.
(A) Gene-expression analysis of undifferentiated ESCs, EBs, and NPCs
mosome 21 compared with chromosomes 20 and 22 as seen by the m
(B) Functional annotation clustering, based on three arrays of WT c
development genes and upregulation of apoptosis-related genes in D
analyzed.
(C) DS-NPCs show downregulation of several key neuro-developmenta
used, for DS, five microarrays of the five independent DS cell lines we
(D) Flow cytometry analysis performed on five DS-NPC lines and th
summation of annexin V+(FITC+)/PI and annexin V+(FITC+)/PI+ cell p
panel) and WT-NPCs (left panel). Bar graph represents the average
percent apoptosis in DS-NPCs and WT-NPCs of all lines used. Error baincreased apoptosis as indicated by our data. In this study,
we disrupted the expression of RUNX1 to demonstrate the
importance of this gene in the phenotypes of DS. Ablation
of RUNX1 resulted in downregulation of key develop-
mental genes and cellular pathways related to neuron
migration and cell growth, with reduced apoptosis in
gene-edited DS-NPCs. These results highlight the impor-
tance of dosage balance of RUNX1 in DS cells. Our results
are supported by a study based on a meta-analysis of DS,
suggesting that RUNX1 is a transcription regulator that
has a global dosage effect on other chromosomes, affecting
genes related to CNS development and neuron differentia-
tion (Vilardell et al., 2011). One hallmark of the facial phe-
notypes of DS patients is a protruding tongue and speech
impediment. It was previously shown that these pheno-
types of DS patients are, at least partially, the result of
abnormal neuromuscular junctions in tongue muscles
(Yarom et al., 1986). Interestingly, a recent study of
RUNX1 demonstrated its involvement in the axonal path-
finding to specific tongue muscles (Yoshikawa et al.,
2015). Our work links the roles of RUNX1 in the develop-
ment of the nervous system to the neural phenotype
observed in DS patients and suggests that this gene carries
out a key function in the development of several of the
phenotypes seen in DS. The expression patterns and role
of RUNX1 in the human developing peripheral and central
nervous systems should be furthered explored. Under-
standing the molecular processes underlying DS will help
in the search for targeted therapy and provide further in-
sights into the genetic dosage imbalance associated with
this syndrome.EXPERIMENTAL PROCEDURES
Derivation of Embryonic Stem Cells with Down
Syndrome
Derivation and characterization of ESCs with trisomy 21 were per-
formed as previously described (Biancotti et al., 2010).of all five DS cell lines show a 1.5-fold higher expression of chro-
oving average plot.
ells and five arrays of DS cells, shows downregulation of forebrain
S-NPCs; only genes that were up- or downregulated by 2-fold were
l genes. For WT, three microarrays of three different cell lines were
re used. Error bars represent SEM.
ree WT-NPC lines exhibits more apoptotic cells in DS cells by the
opulations. Shown are representative results from DS-NPCs (middle
summation of annexin V+/PI and annexin V+/PI+ populations as
rs represent SEM.
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Figure 3. Identification of RUNX1 and
Genetic Editing of DS Cells
(A) Analysis of differentially expressed
genes shows many of the upregulated genes
of more than 2-fold expression to be located
on different chromosomes. Each dot repre-
sents a gene and red lines represent average
fold change in expression for each chro-
mosome between DS- and WT-NPCs.
(B) RUNX1 was found to be a common
transcription factor regulating many of
the upregulated genes in DS-NPCs. Height
of bars represents -log(p value) while
the number inside the bar represents fold
enrichment of the motif in the promoter set
of the upregulated genes in DS-NPCs. RUNX1
resides at chromosome 21q22.12, within
the critical region responsible for DS.
(C) Guide RNA was designed to target the
exon common to all RUNX1 gene isoforms.
Blue letters represent the guide sequence
and red letters represent the PAM sequence
of the guide RNA.
(D) Western blot analysis showing a com-
plete ablation of RUNX1 in edited DS-ESCs
(DSCR), clones DSCR8 and DSCR75 compared
with their parental line (DS) and with WT-
ESCs.Cell Culture
Cell lines used in this study are as follows. For controls, cell lines
CSES7, CSES15, and H9 were used (Biancotti et al., 2010; Lavon
et al., 2008; Narwani et al., 2010; Thomson, 1998). For DS cell
lines we used CSES13, CSES20, CSES21, CSES32, and CSES44 cell
lines. Cell lines CSES13, 20, and 21 were previously described
(Biancotti et al., 2010). Cells were cultured in standard human
ESC culture media containing KnockOut DMEM (Gibco-Invitro-
gen) supplemented with 15% Knockout serum replacement782 Stem Cell Reports j Vol. 7 j 777–786 j October 11, 2016(Gibco-Invitrogen), 2 mM L-glutamine (Sigma-Aldrich), 1:100
dilution of non-essential amino acids (Gibco-Invitrogen),
0.1 mM b-mercaptoethanol (Sigma-Aldrich), 8 ng/mL basic fibro-
blast growth factor (PeproTech), penicillin (50 units/ml), and
streptomycin (50 mg/mL) (Gibco-Invitrogen). Mouse embryonic
fibroblasts (MEFs) were grown in DMEM (Gibco-Invitrogen)
supplemented with 10% FCS (Biological Industries), penicillin
(50 units/ml) and streptomycin (50 mg/mL). EB formation was
described previously (Biancotti et al., 2010). NPC differentiation
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Figure 4. Molecular and Cellular Analysis
of Genomically Edited DS-NPCs
(A) DSCR-NPCs show downregulation of
several key developmental genes, all puta-
tive targets of RUNX1. Microarray expression
data of two DSCR cell lines were compared
with microarray expression data of their
isogeneic parental DS line. DSCR bars repre-
sent the average levels of expression of two
DSCR microarrays.
(B) Several of these genes were further
analyzed for their expression by qRT-PCR
and showed a RUNX1 dosage-dependent
expression pattern in DS-, WT-, and DSCR-
NPCs. For DS, the parental cell line was used
in three independent experiments, for
DSCR, the two isogenic cell lines were used
in three independent experiments, and for
WT, three different cell lines were used.
Error bars represent SEM.
(C) Functional annotation analysis of all
downregulated genes in DSCR-NPCs shows
significant enrichment for neuron migra-
tion, cell migration, and regulation of cell
growth.
(D) Comparison of the apoptotic levels
of the isogenic DS- and DSCR-NPCs were
analyzed and show downregulation of
apoptosis in the edited cells as seen by
the summation of annexin V+(FITC+)/PI
and annexin V+(FITC+)/PI+ cell populations
in DSCR-NPCs (middle panel, representing
one cell line) and DS-NPCs (left panel, rep-
resenting one cell line). Bar graph repre-
sents the average summation of annexin
V+/PI and annexin V+/PI+ populations as
percentage of apoptotic cells. For DS the
parental cell line was used in three inde-
pendent experiments, and for DSCR the two
isogenic cell lines were used in three inde-
pendent experiments. Error bars represent
SEM. *p < 0.05 using Student’s t test.was carried out according to a neural differentiation protocol with
dorsomorphin (Tocris Bioscience) and SB431542 (Cayman Chem-
ical) as described by Kim et al. (2010). NPCs were then sorted
by fluorescence-activated cell sorting for NCAM1-positive cells
with NCAM1 antibody (R&D Systems). Acquisition and sorting
were performed using the FACSAria Cell-Sorting System (Becton
Dickinson).RNA Isolation and Reverse Transcription
RNA was isolated using a PerfectPure RNA Cultured Cell Kit-50
(5 PRIME). One microgram of total RNA was used for reverse tran-
scription reaction using ImProm-II reverse transcriptase (Prom-
ega). For sequencing and quantitative experiments, PCRs were
performed with ReadyMix (Sigma); for overexpression experi-
ments, PCR reactions used Herculase II Fusion DNA polymeraseStem Cell Reports j Vol. 7 j 777–786 j October 11, 2016 783
Table 1. List of Primers
Gene
Symbol Forward Primer Reverse Primer
FEZF2 TATCCACACCCAGGAAAAGC GTGGGTCAGCTTGTGGTTCT
POU3F2 GCGGATCAAACTGGGATTTA AAAGGCTTCAGCTTGCACAT
LHX2 TCTCGGACCGCTACTACCTG GCTACCGTCCTTGCTGAAAC
ASCL1 GTCTCCCGGGGATTTTGTAT AGAGAACTTGGGTGCAGGAA
NR2F1 TACGTGAGGAGCCAGTACCC CCTACCAAACGGACGAAGAA
RFX4 CATCACCAAGCAAACCCTTT GACTCGATGGGAGACTGCTC
IGFBP5 AAGGTGTGGCACTGAAAGTCCC AAGCAGTGCAAACCTTCCCGT
CCL2 TCTCGCCTCCAGCATGAAAGT GCATTGATTGCATCTGGCTGA
LGR5 ACTGCAAACCTGGAGAGTCTGA GATACGCACAGCACTTGGAGAT
FBLN5 TTGCTGCTGATGCTGTGTGTG TGCGGATGTATGTAGGCTGGAG
TLR4 TTTTATCACGGAGGTGGTTCCT CAGGTCCAGGTTCTTGGTTGA
GAPDH AGCCACATCGCTCAGACAC GTACTCAGCGGCCAGCATCG(Agilent Technologies). Real-time qPCRwas performedwith 1 mg of
RNA reverse transcribed to cDNA and TaqMan Universal Master
Mix or SYBR Green qPCR Supermix (see primer list in Table 1;
Applied Biosystems) and analyzedwith the 7300 real-time PCR sys-
tem (Applied Biosystems).
DNA Microarray Analysis
Total RNA was extracted according to the manufacturer’s protocol
(Affymetrix). RNA was subjected to the HG-U133plus2 Affymetrix
microarray platform, as previously described (Biancotti et al., 2010)
or the Human Gene 1.0 ST microarray platform (Affymetrix);
washing and scanning were performed according to the manufac-
turer’s protocol. Arrays were analyzed using Robust Multichip
Analysis in the Affymetrix Expression Console.
Functional Annotations and Motif Search
Functional annotations were done by subjecting differentially ex-
pressed genes to the DAVID functional annotation clustering tool
(http://david.abcc.ncifcrf.gov/) (Huang et al., 2009a, 2009b).
Motifs were searched using the integrated PRIMA and EXPANDER
software (http://acgt.cs.tau.ac.il/prima/) and analyzed for pro-
moter enrichment (Elkon et al., 2003).
Apoptosis Assay and Flow Cytometry Analysis
For quantification of apoptosis, an annexin V-fluorescein isothio-
cyanate (FITC) Apoptosis Detection Kit (eBioscience) was used
according to the manufacturer’s instructions. Cells were then
analyzed using either the FACSCalibur system or the FACSAria
Cell-Sorting system (Becton Dickinson).
Genome Editing by CRISPR/Cas9
Genome editing was performed according to the Ran et al. (2013)
protocol with slight modifications. CRISPR/Cas9 pSpCas9(BB)-2A-
GFP plasmid was obtained from the Addgene repository. CRISPR784 Stem Cell Reports j Vol. 7 j 777–786 j October 11, 2016guide RNA was designed using the CRISPR Design Tool website
(http://crispr.mit.edu/). Oligos for plasmid cloning, F: CACCGAT
GAGCGAGGCGTTGCCGC and R: AAACGCGGCAACGCCTCG
CTCATC, were cloned into the CRISPR/Cas9 plasmid. The
CRISPR/Cas9 plasmid was co-transfected with modified pEGFP-
N1 without GFP by Clontech into DS-ESCs. Selection for positive
clones was carried out with ESC medium containing G418.
Western Blot Analysis
Polyacrylamide gel (8%) was used for protein separation. The
gel was transferred to a nitrocellulose membrane, and antibody
hybridization and chemiluminescence were performed according
to the standard procedures. The primary antibodies used in
this analysis were mouse anti-RUNX1 (A-2) sc-365644 (Santa
Cruz Biotechnology) and anti-GAPDH (14C10; Cell Signaling
Technology). Horseradish peroxidase-conjugated anti-mouse and
anti-rabbit secondary antibodies were obtained from Jackson
ImmunoResearch Laboratories.
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